Table 1.
Patient Characteristics and Treatments
| Patient No. | Gender | Age | Kadish stage | LN meta | Treatment | Surgery | Chemotherapy | Radiation dose |
|---|---|---|---|---|---|---|---|---|
| 1 | F | 22 | B | – | Surgery + PostopRT | TR | – | 65Gy/26Fr |
| 2 | M | 59 | B | – | Surgery + PostopRT | PR | – | 60Gy/30Fr |
| 3 | F | 72 | B | – | Surgery + PostopRT | STR | – | 50Gy/25Fr |
| 4 | M | 53 | C | – | Surgery + PostopRT | STR | – | 56Gy/28Fr |
| 5 | F | 66 | C | RPN | Surgery + PostopRT | TR | – | 65Gy/26Fr |
| 6 | M | 63 | C | – | PreopRT + Surgery | – | 40Gy/20Fr | |
| 7 | M | 55 | C | – | NAC + Surgery + PostopRT | STR | ICE 1 cycle | 65Gy/26Fr |
| 8 | F | 71 | C | – | NAC + Surgery + PostopRT | TR | ICE 1 cycle | 60Gy/30Fr |
| 9 | F | 43 | C | – | NAC + Surgery + PostopRT | TR | ICE 5 cycle | 60Gy/30Fr |
| 10 | M | 37 | C | – | NAC + Surgery + PostopRT | TR | ICE 5 cycles | 60Gy/30Fr |
| 11 | M | 66 | C | – | NAC + Surgery + PostopRT | TR | CDDP | 60Gy/24Fr |
| 12 | F | 44 | C | – | NAC + Surgery + PostopRT | STR | CDDP + ETP | 60Gy/30Fr |
| 13 | M | 46 | C | – | Surgery + Chemo + PostopRT | PR | ICE 2 cycles | 66Gy/33Fr |
| 14 | M | 24 | C | – | NAC + definitive RT | – | CADO/CVP 3 cycle | 54Gy/27Fr |
| 15 | F | 67 | C | ILCN | NAC + definitive RT | – | ICE 2 cycles | 66Gy/33Fr |
| 16 | M | 70 | C | – | NAC + definitive RT | – | CDDP 1 cycles + ICE 2 cycles | 65Gy/26Fr |
| 17 | M | 76 | C | – | definitive RT + Chemo | – | ICE 2 cycles | 65Gy/26Fr |
Abbreviations: RPN (retropharyngeal node), ILCN (ipsilateral cervical node), PostopRT (postoperative radiotherapy), PreopRT (preoperative radiotherapy), NAC (neoadjuvant chemotherapy), TR (total resection), STR (subtotal resection), PR (partial resection), ICE (Ifosfamide, cisplatin and etoposide), CDDP (cisplatin), ETP (etoposide), CADO/CVP (cisplatin, cyclophosphamide, vincristine, etoposide and doxorubicin).